Literature DB >> 31857839

Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors.

Tommi P Kilpeläinen1, Jonna K Tyni2, Maija K Lahtela-Kakkonen2, Tony S Eteläinen1, Timo T Myöhänen1, Erik A A Wallén3.   

Abstract

4-Phenylbutanoyl-aminoacyl-2(S)-tetrazolylpyrrolidines were studied as prolyl oligopeptidase inhibitors. The compounds were more potent than expected from the assumption that the tetrazole would also here be a bioisostere of the carboxylic acid group and the corresponding carboxylic acids are at their best only weak inhibitors. The aminoacyl groups l-prolyl and l-alanyl gave potent inhibitors with IC50 values of 12 and 129 nM, respectively. This was in line with typical prolyl oligopeptidase inhibitors; however, we did observe a difference with N-methyl-l-alanyl, which gave potent inhibitors in typical prolyl oligopeptidase inhibitors but not in our novel compound series. Furthermore, all studied 4-phenylbutanoyl-aminoacyl-2(S)-tetrazolylpyrrolidines decreased α-synuclein dimerization at the concentration of 10 μM, also when they were only weak inhibitors of the proteolytic activity of the enzyme with an IC50 value of 205 μM. Molecular docking studies revealed that the compounds are likely to bind differently to the enzyme compared to typical prolyl oligopeptidase inhibitors represented in this study by 4-phenylbutanoyl-aminoacyl-2(S)-cyanopyrrolidines.
Copyright © 2019 American Chemical Society.

Entities:  

Year:  2019        PMID: 31857839      PMCID: PMC6912865          DOI: 10.1021/acsmedchemlett.9b00394

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  29 in total

1.  A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.

Authors:  T T Myöhänen; M J Hannula; R Van Elzen; M Gerard; P Van Der Veken; J A García-Horsman; V Baekelandt; P T Männistö; A M Lambeir
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids.

Authors:  F Goossens; I De Meester; G Vanhoof; S Scharpé
Journal:  Eur J Clin Chem Clin Biochem       Date:  1996-01

3.  Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819.

Authors:  Jarkko I Venäläinen; Risto O Juvonen; Markus M Forsberg; Arturo Garcia-Horsman; Antti Poso; Erik A A Wallen; Jukka Gynther; Pekka T Männistö
Journal:  Biochem Pharmacol       Date:  2002-08-01       Impact factor: 5.858

4.  Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein.

Authors:  Inger Brandt; Melanie Gérard; Kjell Sergeant; Bart Devreese; Veerle Baekelandt; Koen Augustyns; Simon Scharpé; Yves Engelborghs; Anne-Marie Lambeir
Journal:  Peptides       Date:  2008-05-15       Impact factor: 3.750

5.  The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Authors:  Mari H Savolainen; Christopher T Richie; Brandon K Harvey; Pekka T Männistö; Kathleen A Maguire-Zeiss; Timo T Myöhänen
Journal:  Neurobiol Dis       Date:  2014-04-16       Impact factor: 5.996

6.  Synthesis and structure-activity relationships of peptidyl alpha-keto heterocycles as novel inhibitors of prolyl endopeptidase.

Authors:  S Tsutsumi; T Okonogi; S Shibahara; S Ohuchi; E Hatsushiba; A A Patchett; B G Christensen
Journal:  J Med Chem       Date:  1994-10-14       Impact factor: 7.446

7.  Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor.

Authors:  Teresa Tarragó; Nessim Kichik; Birgit Claasen; Roger Prades; Meritxell Teixidó; Ernest Giralt
Journal:  Bioorg Med Chem       Date:  2008-04-29       Impact factor: 3.641

8.  Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity.

Authors:  Elena Di Daniel; Colin P Glover; Emma Grot; Man K Chan; Thirza H Sanderson; Julia H White; Catherine L Ellis; Kathleen T Gallagher; James Uney; Julia Thomas; Peter R Maycox; Anne W Mudge
Journal:  Mol Cell Neurosci       Date:  2009-03-28       Impact factor: 4.314

9.  Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.

Authors:  D Mantle; G Falkous; S Ishiura; P J Blanchard; E K Perry
Journal:  Clin Chim Acta       Date:  1996-05-30       Impact factor: 3.786

10.  New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro.

Authors:  Raj Kumar; Rohit Bavi; Min Gi Jo; Venkatesh Arulalapperumal; Ayoung Baek; Shailima Rampogu; Myeong Ok Kim; Keun Woo Lee
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

View more
  2 in total

1.  Therapeutic Effect of Novel Cyanopyrrolidine-Based Prolyl Oligopeptidase Inhibitors in Rat Models of Amnesia.

Authors:  Nikolay N Zolotov; Igor A Schepetkin; Tatyana A Voronina; Vladimir F Pozdnev; Andrei I Khlebnikov; Irina V Krylova; Mark T Quinn
Journal:  Front Chem       Date:  2021-12-22       Impact factor: 5.221

2.  Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy.

Authors:  Hengjing Cui; Tommi Kilpeläinen; Lydia Zouzoula; Samuli Auno; Kalevi Trontti; Sampo Kurvonen; Susanna Norrbacka; Iiris Hovatta; Poul Henning Jensen; Timo T Myöhänen
Journal:  J Cell Mol Med       Date:  2021-09-05       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.